ClinicalTrialsFinder
RecruitingPhase 1NCT07189195

TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma

A Phase 1 Study of Bisaminoquinoline Derivative (TR-002) for Injection for Advanced Treatment-Refractory Solid Tumors

Sponsor

University of California, Davis

Enrollment

52 participants

Start Date

Nov 7, 2025

Study Type

INTERVENTIONAL

Conditions

Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmStage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Advanced Malignant Solid NeoplasmUnresectable Pancreatic AdenocarcinomaMetastatic Pancreatic AdenocarcinomaRefractory Pancreatic Adenocarcinoma

Summary

This phase I trial tests the safety, side effects and best dose of TR-002 for the treatment of solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced), that cannot be removed by surgery (unresectable), that has spread from where it first started (primary site) to other places in the body (metastatic) and unresectable or metastatic pancreatic adenocarcinoma that does not respond to treatment (refractory). Chemotherapy drugs, such as TR-002, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. TR-002 may be safe and tolerable in treating patients with advanced, unresectable or metastatic solid tumors and unresectable or metastatic, refractory pancreatic adenocarcinoma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new experimental treatment called TR-002 for people with advanced solid tumors, including a special focus on pancreatic cancer that has stopped responding to all standard treatments. **You may be eligible if...** - You are 18 or older - You have advanced or metastatic solid tumor cancer that no longer responds to standard treatments or that you could not tolerate - For the pancreatic cancer group: your cancer has not responded to all standard chemotherapy options (gemcitabine, nab-paclitaxel, fluoropyrimidine, oxaliplatin, irinotecan) - You are well enough to participate (ECOG 0–2) - Your heart, liver, kidneys, and blood counts are adequate **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have severely impaired organ function - You are unable to use contraception if you are of reproductive age Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTR-002

Weekly intravenous infusion

Locations(1)

University of California Davis Comprehensive Cancer Center

Sacramento, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07189195

Related Trials

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

NCT05564377479 locations

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

NCT0541109411 locations

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

NCT072142981 location

Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

NCT0568711023 locations

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

NCT0568560226 locations